The Effectiveness of Naltrexone in Treating Task Attending, Aggression, Self-Injury, and Stereotypic Mannerisms of Six Young Males with Autism or Pervasive Developmental Disorders

Journal of Developmental and Physical Disabilities

Volumn 9, Issue 3, 1997, Pages 211-221

  Anderson, Steven ^a   Hanson, Ronald ^a   Malecha, Myron ^a   Oftelie, Arla ^a   Erickson, Cynthia ^a   Clark, Jane Moore ^a  

^a Mt Olivet Rolling Acres   (United States)

Author keywords

Aggression; Autism; Naltrexone; Pervasive developmental disorders; Self injury

Indexed keywords

EID: 0031513395     PISSN: 1056263X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024933904144     Document Type: Article

References (36)

1. Aman, M. G., Singh, N. N., Stewart, A. W., and Field, C. J. (1985a). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. Am. J. Ment. Def. 89: 485-491.
2. Aman, M. G., Singh, N. N., Stewart, A. W., and Field, C. J. (1985b). Psychometric characteristics of the Aberrant Behavior Checklist. Am. J. Ment. Def. 89: 492-502.
3. American Psychiatric Association. (1987). Diagnostic and Statistical Manual of Mental Disorders DSM-III-R (3rd ed., revised), Washington, D.C.: Author.
4. Benjamin, S., Seek, A., Tresise, L., Price, E. and Gagnon, M. (1995). Case study: Paradoxical response to naltrexone treatment of self-injurious behavior. J. Am. Acad. Child Adol. Psychiatry 34: 238-242.
5. Campbell, M., Adams, P., Small, A. M., Tesch, L. M., and Curren, E. L. (1988). Naltrexone in infantile autism. Psychopharmacol. Bull. 24: 135-139.
6. Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N., and Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. J. Am. Acad. Child Adol. Psychiatry 32: 1283-1291.
7. Campbell, M., Anderson, L. T., Small, A. M., Locascio, J. J., Lynch, N. S., and Choroco, M. C. (1990). Naltrexone in autistic children: A double-blind and placebo-controlled study. Psychopharmacol Bull. 26: 130-135.
8. Campbell, M., Overall, J. E., Small, A. M., Sokol, M. S., Spencer, E. K., Adams, P., Foltz, R. L., Monti, K. M., Perry, R., Nobler, M., and Roberts, E. (1989). Naltrexone in autistic children: An acute open dose range tolerance trial. J. Am. Acad. Child Adol. Psychiatry 28: 200-206.
9. Cataldo, M., and Harris, J. (1982). The biological basis for self-injury in the mentally retarded. Anal. Intervent. Devel. Dis. 2: 21-39.
10. Deutsch, S. I. (1986). Rationale for the administration of opiate antagonists in treating infantile autism. Am. J. Ment. Retard. 90: 631-635.
11. Duker, P. C., Welles, K., Seys, D., Rensen, H., Vis, A., and van den Berg, G. (1991). Brief report: Effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistic-type mentally handicapped individuals. J. Aut. Devel. Dis. 21: 355-363.
12. Ernst, M., Devi, L., Silva, R. R., Gonzalez, N. M., Small, A. M., Malone, R. P., and Campbell, M. (1993). Plasma beta-endorphin levels, naltrexone, and Haloperidol in autistic children. Psychopharmacol Bull 29(2): 221-227.
13. Gillberg, C., Terenius, L., and Lonnerholm, G. (1985). Endorphin activity in childhood psychosis. Arch. Gen. Psychiatry 42: 780-783.
14. Gonzalez, N. M., Campbell, M., Small, A. M., Shay, J., Bluhm, L. D., Adams, P. B. and Frotz, R. L. (1994). Naltrexone plasma levels, clinical response and effect on weight in autistic children. Psychoparmacol. Bull. 30(2): 203-208.
15. Herman, B. H. (1991). Effects of opioid receptor antagonists in the treatment of autism and self-injurious behavior. In Ratey, J. J. (ed.), Mental Retardation: Developing Pharmacotherapies. American Psychiatric Press, Washington, DC, pp. 107-137.
16. Herman, B. H., Hammock, M. K., Arthur-Smith, A., Egan, J., Chatoor, I., Werner, A., and Zelnik, N. (1987). Naltrexone decreases self-injurious behavior. Ann. Neurol. 22: 550-552.
17. Herman, B. H., Hammock, M. K., Arthur-Smith, A., Kuehl, K., and Applegate, K. (1989). Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children. Devel. Pharmacol. Ther. 12: 118-127.
18. Knabe, R., Schulz, P., and Richard, J. (1990). Initial aggravation of self-injurious behavior in autistic patients receiving naltrexone treatment. J. Aut. Devel. Dis. 20: 591-593.
19. Kolmen, B. K., Feldman, H. M., Handen, B. L., and Janosky, J. E. (1995). Naltrexone in young autistic children: A double-blind, placebo-controlled crossover study. J. Am. Acad. Child Psychiatry 34: 223-231.
20. Krug, D., Arick, J., and Almond P. (1980). Autism Screening Instrument for Educational Planning, ASIEP Education Company, Portland, Oregon.
21. Leboyer, M., Bouvard, M. P., and Dugas, M. (1988). Effects of naltrexone on infantile autism. Lancet 1: 715.
22. Leboyer, M., Bouvard, M. P., Launay, J. M., Tabuteau, F., Waller, D., Dugas, M., Kerdelhue, B., Lensing, P., and Panksepp, J. (1992). Brief report: A double-blind study of naltrexone in infantile autism. J. Aut. Devel Dis. 22: 309-319.
23. Lensing, P., Klingler, D., Lampl, C., Leboyer, M., Bouvard, M., Plumet, M. H., and Panksepp, J. (1992). Naltrexone open trial with a 5-year-old boy: A social rebound reaction. Acta Paedopsychiatr. 55: 169-173.
24. Panksepp, J. (1979). A neurochemical theory of autism. Trends Neurosci. 2: 174-177.
25. Panksepp, J., and Lensing, P. (1991). Brief report: A synopsis of an open-trial of naltrexone treatment of autism with four children. J. Aut. Devel. Dis. 21: 243-249.
26. Ross, D. L., Klykylo, W. M., and Hitzemann, R. (1987). Reduction of elevated CSF beta-endorphin by fenfluramine in infantile autism. Pediatr. Neurol. 3: 83-86.
27. Sandman, C. A. (1988). B-Endorphin disregulation in autistic and self-injurious behavior: A neurodevelopmental hypothesis. Synapse 2: 193-199.
28. Sandman, C. A., Hetrick, W. P., Taylor, D. V., Barron, J. L., Touchette, P., Lott, I., Crinella, F., and Martinazzi, V. (1993). Naltrexone reduces self-injury and improves learning. Exp. Clin. Psychopharmacol. 1: 242-258.
29. Sandman, C. A., Thompson, T., Barrett, R. P., Verhoeven, W. M. A., McCubbin, J. A., Schroeder, S. R., and Hetrick, W. P. Opiate blockers (In Press). In Reiss, S. and Aman, M. G. (eds.), Psychoactive Drugs and Developmental Disabilities: The International Consensus Handbook, The Nisonger Center, Columbus, OH.
30. Siegel, S. (1956). Nonparametric Statictics for the Behavioral Sciences. McGraw-Hill, New York.
31. Sulzer-Azaroff, B., and Mayer, G. R. (1977). Applying Behavior-Analysis Procedures with Children and Youth. Holt, Reinhart, and Winston, New York, NY.
32. Taylor, D. V., Sandman, C. A., Touchette, P., Hetrick, W. P., and Barron, J. L. (1993). Naltrexone improves learning and attention in self-injurious individuals with developmental disabilities. J. Devel. Phys. Dis. 5: 29-42.
33. Thompson, T., Hackenberg, T., Cerutti, D., Baker, D., and Axtell, S. (1994). Opioid antagonist effects on self-injury in adults with mental retardation: response form and location as determinants of medication effects. Am. J. Ment. Retard., 99: 85-102.
34. Walters, A. S., Barrett, R. P., Feinstein, C., Mercurio, A., and Hole, W. T. (1990). A case report of naltrexone treatment of self-injury and social withdrawal in autism. J. Aut. Devel. Dis. 20: 169-176.
35. Wheeler, D. L., Jacobson, J. W., Paglieri, R. A., and Schwartz, A. A. (1993). An experimental assessment of facilitated communication. Ment. Retard. 31: 49-60.
36. Zingarelli, G., Ellman, G., Hom, A., Wymore, M., Heidorn, S., and Chicz-DeMet, A. (1992). Clinical effects of naltrexone on autistic behavior. Am. J. Ment. Retard., 97: 57-63.